Moberg Pharma | MOB - Profile, Filings, Stock Info & Investor Relations Data

s of April 2019, Moberg Pharma focuses on the commercialization of its clinical pipeline with a combined peak sales potential estimated at USD 350–700 million. MOB-015 is a next generation nail fungus treatment, and BUPI is a novel treatment for oral pain relief in association with inflammation and ulceration of the oral mucous membranes (oral mucositis or OM), a serious complication of cancer treatment. Both drugs have demonstrated strong clinical results which indicate that they have the potential to become market leaders in their respective niches.

Moberg Pharma has secured commercialization partners for MOB-015 in Europe, Japan, Canada, Israel and the Republic of Korea. MOB-015 has recently been evaluated over 52 weeks in two randomized, multicenter, controlled Phase 3 studies, including in total more than 800 patients in North America and Europe. The primary endpoint was met in both studies, the proportion of patients achieving complete cure of their target nail.